Anti-Infective Drugs Market Research Report: Market size, Industry outlook, Market Forecast, Demand Analysis,Market Share, Market Report 2018-2023
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Anti-Infective Drugs Market
Anti-Infective Drugs Market: By Drug Type (Antifungals, Antibacterials and Antivirals); By Infection Type(HIV, Hepatitis B, Hepatitis C, Urinary Tract, Respiratory Candidiasis, and Others); and By Geography (Europe, APAC, North America, ROW) –Forecast (2018-2023)
Report Code : HCR 0149
Updated Date: 10 May, 2018  

1. Anti-Infective Drugs – Market Overview
2. Executive Summary
3. Anti-Infective Drugs Market Landscape

   3.1. Market Share Analysis
   3.2. Comparative Analysis
      3.2.1. Product Benchmarking
      3.2.2. End User Profiling
      3.2.3. Top 5 Financials Analysis
4. Anti-Infective Drugs – Market Forces
   4.1. Drivers
      4.1.1. Increasing number of patients pool globally
      4.1.2. Increasing drug approval
   4.2. Restraints
      4.2.1. Possible side effects over a long term
   4.3. Opportunities
   4.4. Challenges
   4.5. Porter’s Five Forces Analysis
      4.5.1. Bargaining Power of Suppliers
      4.5.2. Bargaining Power of Buyers
      4.5.3. Threat of New Entrants
      4.5.4. Threat of Substitutes
      4.5.5. Degree of Competition
5. Anti-Infective Drugs Market – Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Pricing Analysis
   5.3. Opportunities Analysis
   5.4. Product/Market Life Cycle Analysis
   5.5. Suppliers and Distributors
6. Anti-Infective Drugs Market, By Drugs Type
   6.1. Antifungals
      6.1.1. Allylamines
      6.1.2. Azoles
      6.1.3. Polyene Macrolides
      6.1.4. Other Antifungals Diuretics
   6.2. Antibacterials
      6.2.1. Aminoglycosides
      6.2.2. Carbapenems
      6.2.3. Cephalosporins
      6.2.4. Macrolides
      6.2.5. Penicillins
      6.2.6. Quinolones
      6.2.7. Sulfonamides
      6.2.8. Tetracyclines
      6.2.9. Others Calcium channel blockers
   6.3. Antivirals
      6.3.1. Nucleoside Analogs
      6.3.2. Transcriptase Inhibitors
      6.3.3. DNA Polymerase Inhibitors
      6.3.4. Protease Inhibitors
      6.3.5. Other Antivirals Angiotensin-converting enzyme (ACE) inhibitors
7. Anti-Infective Drugs Market, By Infection
   7.1. HIV
   7.2. Hepatitis B
   7.3. Hepatitis C
   7.4. Urinary Tract
   7.5. Respiratory Candidiasis
   7.6. Other Infections
8. Anti-Infective Drugs Market, By Geography
   8.1. Europe
      8.1.1. Germany
      8.1.2. France
      8.1.3. Italy
      8.1.4. Spain
      8.1.5. Russia
      8.1.6. U.K.
      8.1.7. Rest of Europe
   8.2. Asia Pacific
      8.2.1. China
      8.2.2. India
      8.2.3. Japan
      8.2.4. South Korea
      8.2.5. Rest of Asia-Pacific
   8.3. North America
      8.3.1. U.S.
      8.3.2. Canada
      8.3.3. Mexico
   8.4. Rest of the World (RoW)
      8.4.1. Brazil
      8.4.2. Rest of RoW
9. Anti-Infective Drugs – Market Entropy
   9.1. Expansion
   9.2. Technological Developments
   9.3. Merger & Acquisitions, and Joint Ventures
   9.4. Supply- Contract
10. Company Profiles
   10.1. Abbott Laboratories
      10.1.1.  Introduction
      10.1.2. Financials
      10.1.3. Key Insights
      10.1.4. Key Strategy
      10.1.5. Product Portfolio
      10.1.6. SWOT Analysis
   10.2. Alcon Pharmaceuticals Ltd.  
      10.2.1. Introduction
      10.2.2. Financials
      10.2.3. Key Insights
      10.2.4. Key Strategy
      10.2.5. Product Portfolio
      10.2.6. SWOT Analysis
   10.3. Astellas Pharma Inc.   
      10.3.1.  Introduction
      10.3.2. Financials
      10.3.3. Key Insights
      10.3.4. Key Strategy
      10.3.5. Product Portfolio
      10.3.6. SWOT Analysis
   10.4. AstraZeneca Plc     
      10.4.1. Introduction
      10.4.2. Financials
      10.4.3. Key Insights
      10.4.4. Key Strategy
      10.4.5. Product Portfolio
      10.4.6. SWOT Analysis
   10.5. Bayer HealthCare AG    
      10.5.1. Introduction
      10.5.2. Financials
      10.5.3. Key Insights
      10.5.4. Key Strategy
      10.5.5. Product Portfolio
      10.5.6. SWOT Analysis
   10.6. Bristol-Myers Squibb Co.    
      10.6.1. Introduction
      10.6.2. Financials
      10.6.3. Key Insights
      10.6.4. Key Strategy
      10.6.5. Product Portfolio
      10.6.6. SWOT Analysis
   10.7. Boehringer Ingelheim  
      10.7.1. Introduction
      10.7.2. Financials
      10.7.3. Key Insights
      10.7.4. Key Strategy
      10.7.5. Product Portfolio
      10.7.6. SWOT Analysis
   10.8. Sanofi-Aventis SA     
      10.8.1. Introduction
      10.8.2. Financials
      10.8.3. Key Insights
      10.8.4. Key Strategy
      10.8.5. Product Portfolio
      10.8.6. SWOT Analysis
   10.9. Novartis AG
      10.9.1. Introduction
      10.9.2. Financials
      10.9.3. Key Insights
      10.9.4. Key Strategy
      10.9.5. Product Portfolio
      10.9.6. SWOT Analysis
   10.10. GlaxoSmithKline Plc     
      10.10.1. Introduction
      10.10.2. Financials
      10.10.3. Key Insights
      10.10.4. Key Strategy
      10.10.5. Product Portfolio
      10.10.6. SWOT Analysis
*More than 10 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
11. Appendix
   11.1. Abbreviations
   11.2. Sources
   11.3. Research Methodology
   11.4. Bibliography
   11.5. Compilation of Expert Insights
   11.6. Disclaimer
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports
0px;">Scroll